Prescriptions of Eisai’s Aricept To New Patients Below 50%
This article was originally published in PharmAsia News
Executive Summary
According to research carried out by the Japan Medical Information Research Institute, the share of new patients being prescribed Eisai’s Alzheimer drug Aricept in August 2012 decreased to just 45% due to the increase in generic drugs and the end of limits to long-term prescriptions.